Lupin Reports Strong PAT Growth Amid Rising Interest Expenses in May 2025 Results

Lupin, a prominent player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending March 2025. The results, declared on May 14, 2025, indicate a notable adjustment in evaluation, with the stock's score shifting to 4 from 17 over the past three months. In terms of performance, Lupin's Profit After Tax (PAT) for the latest six months stands at Rs 1,627.68 crore, reflecting a year-on-year growth of 67.36%. This positive trend in PAT suggests a robust near-term outlook for the company. Conversely, the financial results also highlight challenges for Lupin. The quarterly interest expense has reached Rs 89.10 crore, marking the highest level in the last five quarters and an increase of 33.20% quarter on quarter. This rise in interest costs indicates a potential increase in borrowings, which may impact the company's financial structure. Overall, Lupin's recent financial disclosures reveal a complex landscape of growth in profitability alongside rising financial costs, leading to a revision in its score. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.